Clinical Trial Update: Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction [Phase 4]

View source ↗

Summary

Phase 4 trial comparing TauroLock-based catheter lock regimen with 4% citrate in tunneled hemodialysis catheters to prevent bacteremia and catheter dysfunction;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catheter-related Bloodstream Infection
• End-stage Renal Disease

Drugs mentioned

• 4% Citrate (sodium citrate 4% catheter lock solution)
• TauroLock (taurolidine)

Snippet

Sponsor: Medical University of Vienna | Conditions: Catheter Infections, End-stage Renal Disease | Phase 4 | Status: COMPLETED